Casey D. Katerndahl, PhD
Assistant Professor of Pathology & Laboratory Medicine
- ckaternd@iu.edu
- Phone
- 317-278-3099
- Address
-
Walther Hall (R3 C345)
980 W. Walnut St.
Indianapolis, IN 46202 - PubMed:
-
Bio
Approximately 20,000 adult patients develop acute myeloid leukemia (AML) each year; these patients have a ~25% chance to survive five years after their initial diagnosis. This is largely due to relapses, refractory disease, or serious side effects associated with current therapies (i.e. chemotherapy and/or blood stem cell transplantation). To develop better treatment strategies, we must first understand the underlying molecular mechanisms that initiate and maintain the disease.
Our lab utilizes state-of-the-art techniques to elucidate the mechanisms that control the aberrant self-renewal and transformation of myeloid progenitor cells. A greater understanding of these processes may help us to design novel therapeutic strategies to more specifically and effectively treat AML. In addition, identifying the genes and mechanisms that control self-renewal could have important implications for regenerative medicine and stem cell biology.
| Year | Degree | Institution |
|---|---|---|
| 2020 | Postdoctoral Training | Washington University |
| 2017 | Postdoctoral Training | University of Minnesota |
| 2015 | PhD | University of Minnesota |
| 2008 | BS | University of Minnesota |
We are interested in understanding the molecular mechanisms by which inherited mutations in the transcription factor GATA2 lead to GATA2 deficiency syndrome and acute myeloid leukemia (AML). To this end, we have developed a novel Gata2T354M knock-in mouse model and are using multi-omic approaches. This aim is part of a broader strategy to identify and functionally pathways regulated by GATA2 that are functionally relevant for the pathogenesis of acute myeloid leukemia, and to develop novel ways to manipulate these pathways for therapeutic benefit.